6UI Stock Overview
A biopharmaceutical company, focuses on developing products in diabetes and other indications ion the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Arecor Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.89 |
| 52 Week High | UK£2.26 |
| 52 Week Low | UK£0.72 |
| Beta | -0.27 |
| 11 Month Change | 2.31% |
| 3 Month Change | -13.24% |
| 1 Year Change | -57.04% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -68.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6UI | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.6% | -1.0% | -0.5% |
| 1Y | -57.0% | -16.7% | 8.3% |
Return vs Industry: 6UI underperformed the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: 6UI underperformed the German Market which returned 8.3% over the past year.
Price Volatility
| 6UI volatility | |
|---|---|
| 6UI Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6UI has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 6UI's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 50 | Sarah Howell | arecor.com |
Arecor Therapeutics plc, a biopharmaceutical company, focuses on developing products in diabetes and other indications ion the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo which is used to treat severe hypoglycaemia events in patients with diabetes; and specialty hospital products.
Arecor Therapeutics plc Fundamentals Summary
| 6UI fundamental statistics | |
|---|---|
| Market cap | €34.59m |
| Earnings (TTM) | -€10.38m |
| Revenue (TTM) | €5.87m |
5.9x
P/S Ratio-3.3x
P/E RatioIs 6UI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6UI income statement (TTM) | |
|---|---|
| Revenue | UK£4.90m |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£4.90m |
| Other Expenses | UK£13.57m |
| Earnings | -UK£8.67m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 100.00% |
| Net Profit Margin | -176.89% |
| Debt/Equity Ratio | 0% |
How did 6UI perform over the long term?
See historical performance and comparison